123 related articles for article (PubMed ID: 21516785)
41. Anti-diabetic effects of cesium aqua (N,N'-ethylene(salicylideneiminato)-5-sulfonato) oxovanadium (IV) dihydrate in streptozotocin-induced diabetic rats.
Li M; Wei D; Ding W; Baruah B; Crans DC
Biol Trace Elem Res; 2008 Mar; 121(3):226-32. PubMed ID: 17968514
[TBL] [Abstract][Full Text] [Related]
42. Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction.
Yao J; Battell ML; McNeill JH
Can J Physiol Pharmacol; 1997 Feb; 75(2):83-90. PubMed ID: 9114928
[TBL] [Abstract][Full Text] [Related]
43. In vitro study of the insulin-like action of vanadyl-pyrone and -pyridinone complexes with a VO(O4) coordination mode.
Rangel M; Tamura A; Fukushima C; Sakurai H
J Biol Inorg Chem; 2001 Feb; 6(2):128-32. PubMed ID: 11293405
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic study on gastrointestinal absorption of insulinomimetic vanadyl complexes in rats by ESR spectroscopy.
Fugono J; Yasui H; Sakurai H
J Pharm Pharmacol; 2001 Sep; 53(9):1247-55. PubMed ID: 11578107
[TBL] [Abstract][Full Text] [Related]
45. Bis(allixinato)oxovanadium(IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes.
Adachi Y; Yoshida J; Kodera Y; Katoh A; Takada J; Sakurai H
J Med Chem; 2006 Jun; 49(11):3251-6. PubMed ID: 16722643
[TBL] [Abstract][Full Text] [Related]
46. [Hypoglycemic effects of peroxovanadate complexes on glucose transportor of diabetic rats].
Yuan M; Yu B; Liang Y
Zhonghua Yi Xue Za Zhi; 1997 Mar; 77(3):208-11. PubMed ID: 9596962
[TBL] [Abstract][Full Text] [Related]
47. Effects of peroxovanadate complexes on reducing glycemia in diabetic rats and translocation of glucose transporter.
Yuan M; Yu B; Liang Y
Chin Med J (Engl); 1997 Sep; 110(9):715-9. PubMed ID: 9642333
[TBL] [Abstract][Full Text] [Related]
48. The effects of vanadium treatment on bone in diabetic and non-diabetic rats.
Facchini DM; Yuen VG; Battell ML; McNeill JH; Grynpas MD
Bone; 2006 Mar; 38(3):368-77. PubMed ID: 16256449
[TBL] [Abstract][Full Text] [Related]
49. Hypoglycemic activity of curcumin synthetic analogues in alloxan-induced diabetic rats.
Das KK; Razzaghi-Asl N; Tikare SN; Di Santo R; Costi R; Messore A; Pescatori L; Crucitti GC; Jargar JG; Dhundasi SA; Saso L
J Enzyme Inhib Med Chem; 2016; 31(1):99-105. PubMed ID: 25683079
[TBL] [Abstract][Full Text] [Related]
50. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
[TBL] [Abstract][Full Text] [Related]
51. Streptozotocin-induced alterations in rat liver Golgi complexes are ameliorated by BMOV [Bis(maltolato)oxovanadium(IV)] activity.
Kordowiak AM; Dziga D; Dabroś W
Horm Metab Res; 2004 Mar; 36(3):148-54. PubMed ID: 15057667
[TBL] [Abstract][Full Text] [Related]
52. [Hypoglycemic effects of bis(maltolato)oxovanadium administered by different routes upon diabetic rats].
Zhong XY; Zhang H; Zhang X; Lv WL; Zhang Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Jun; 36(3):313-8. PubMed ID: 15205708
[TBL] [Abstract][Full Text] [Related]
53. Effect of oxovanadium(IV) complexes on nondiabetic and streptozotocin-diabetic rats.
Krosniak M; Zachwieja Z; Filipek B; Zygmunt M; Grybos R
Arch Pharm (Weinheim); 2001 Dec; 334(12):388-92. PubMed ID: 11852534
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and hypoglycemic activity of some new theophylline derivatives.
Alafeefy AM; Alqasoumi SI; Abdel Hamid SG; El-Tahir KE; Mohamed M; Zain ME; Awaad AS
J Enzyme Inhib Med Chem; 2014 Jun; 29(3):443-8. PubMed ID: 23701264
[TBL] [Abstract][Full Text] [Related]
55. Heteroleptic oxidovanadium(IV)-malate complex improves glucose uptake in HepG2 and enhances insulin action in streptozotocin-induced diabetic rats.
de Nigro TP; Manica GCM; de Souza SW; Jesus CHA; Bottini RCR; Missina JM; Valdameri G; Nunes GG; da Cunha JM; Picheth G; Rego FGM
Biometals; 2022 Oct; 35(5):903-919. PubMed ID: 35778658
[TBL] [Abstract][Full Text] [Related]
56. Synthesis, characterization and antidiabetic properties of N(1)-2,4-dihydroxybenzylidene-N(4)-2-hydroxybenzylidene-S-methyl-thiosemicarbazidato-oxovanadium(IV).
Yanardag R; Demirci TB; Ulküseven B; Bolkent S; Tunali S; Bolkent S
Eur J Med Chem; 2009 Feb; 44(2):818-26. PubMed ID: 18621448
[TBL] [Abstract][Full Text] [Related]
57. Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats.
Cam MC; Faun J; McNeill JH
Metabolism; 1995 Mar; 44(3):332-9. PubMed ID: 7885278
[TBL] [Abstract][Full Text] [Related]
58. Vanadyl-thiazolidinedione combination agents for diabetes therapy.
Storr T; Mitchell D; Buglyó P; Thompson KH; Yuen VG; McNeill JH; Orvig C
Bioconjug Chem; 2003; 14(1):212-21. PubMed ID: 12526711
[TBL] [Abstract][Full Text] [Related]
59. In vivo coordination structural changes of a potent insulin-mimetic agent, bis(picolinato)oxovanadium(IV), studied by electron spin-echo envelope modulation spectroscopy.
Fukui K; Fujisawa Y; OhyaNishiguchi H; Kamada H; Sakurai H
J Inorg Biochem; 1999; 77(3-4):215-24. PubMed ID: 10643660
[TBL] [Abstract][Full Text] [Related]
60. Influence of bis(maltolato)oxovanadium(IV) on activity of galactosyltransferase (GalT) and morphology of rat liver Golgi apparatus in control and streptozotocin diabetes.
Dabroś W; Kordowiak AM; Dziga D; Gryboś R
Pol J Pathol; 1998; 49(2):67-76. PubMed ID: 9798409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
